Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

BACKGROUND: Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell exhaustion and thus enhancing anti-PD-1/PD-L1 efficacy. METHODS: This phase I/II st...

Descripción completa

Detalles Bibliográficos
Autores principales: Zucali, Paolo Andrea, Lin, Chia-Chi, Carthon, Bradley C, Bauer, Todd M, Tucci, Marcello, Italiano, Antoine, Iacovelli, Roberto, Su, Wu-Chou, Massard, Christophe, Saleh, Mansoor, Daniele, Gennaro, Greystoke, Alastair, Gutierrez, Martin, Pant, Shubham, Shen, Ying-Chun, Perrino, Matteo, Meng, Robin, Abbadessa, Giovanni, Lee, Helen, Dong, Yingwen, Chiron, Marielle, Wang, Rui, Loumagne, Laure, Lépine, Lucie, de Bono, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783811/
https://www.ncbi.nlm.nih.gov/pubmed/35058326
http://dx.doi.org/10.1136/jitc-2021-003697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783811/
https://www.ncbi.nlm.nih.gov/pubmed/35058326
http://dx.doi.org/10.1136/jitc-2021-003697

Ejemplares similares